» Articles » PMID: 23318118

Using Body Mass Index to Predict Optimal Thyroid Dosing After Thyroidectomy

Overview
Journal J Am Coll Surg
Date 2013 Jan 16
PMID 23318118
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Current postoperative thyroid replacement dosing is weight based, with adjustments made after thyroid-stimulating hormone values. This method can lead to considerable delays in achieving euthyroidism and often fails to accurately dose over- and underweight patients. Our aim was to develop an accurate dosing method that uses patient body mass index (BMI) data.

Study Design: A retrospective review of a prospectively collected thyroid database was performed. We selected adult patients undergoing thyroidectomy, with benign pathology, who achieved euthyroidism on thyroid hormone supplementation. Body mass index and euthyroid dose were plotted and regression was used to fit curves to the data. Statistical analysis was performed using STATA 10.1 software (Stata Corp).

Results: One hundred twenty-two patients met inclusion criteria. At initial follow-up, only 39 patients were euthyroid (32%). Fifty-three percent of patients with BMI >30 kg/m(2) were overdosed, and 46% of patients with BMI <25 kg/m(2) were underdosed. The line of best fit demonstrated an overall quadratic relationship between BMI and euthyroid dose. A linear relationship best described the data up to a BMI of 50. Beyond that, the line approached 1.1 μg/kg. A regression equation was derived for calculating initial levothyroxine dose (μg/kg/d = -0.018 × BMI + 2.13 [F statistic = 52.7, root mean square error of 0.24]).

Conclusions: The current standard of weight-based thyroid replacement fails to appropriately dose underweight and overweight patients. Body mass index can be used to more accurately dose thyroid hormone using a simple formula.

Citing Articles

Gender, FT4 levels, T stage, and BMI as predictors of TSH levels in thyroid cancer patients.

Zhang S, Niu S, Zhou L Front Endocrinol (Lausanne). 2025; 16:1422464.

PMID: 39926345 PMC: 11802359. DOI: 10.3389/fendo.2025.1422464.


Analysis of factors influencing the dose of levothyroxine treatment in adequately controlled hypothyroid patients of different etiologies.

Stempler M, Bakos B, Solymosi T, Kiss A, Armos R, Szili B Heliyon. 2024; 10(20):e39639.

PMID: 39502224 PMC: 11535356. DOI: 10.1016/j.heliyon.2024.e39639.


A predictive model for L-T4 dose in postoperative DTC after RAI therapy and its clinical validation in two institutions.

Liu J, Wang Z, Yue Y, Yin G, Tong L, Fu J Front Endocrinol (Lausanne). 2024; 15:1425101.

PMID: 39229373 PMC: 11368713. DOI: 10.3389/fendo.2024.1425101.


Adequate Dose of Levothyroxine for Thyroid-Stimulating Hormone Suppression after Total Thyroidectomy in Patients with Differentiated Thyroid Cancer.

Ryu H, Choi M, Park H, Kim T, Chung J, Park S Endocrinol Metab (Seoul). 2024; 39(4):615-621.

PMID: 39111780 PMC: 11375304. DOI: 10.3803/EnM.2023.1896.


Optimizing Thyroxine Dosage After Total Thyroidectomy: Understanding the Factors at Play.

Dawn Paul E, T V S, Sulaiman S Cureus. 2024; 16(4):e58430.

PMID: 38765445 PMC: 11099504. DOI: 10.7759/cureus.58430.


References
1.
Toft A . Thyroxine therapy. N Engl J Med. 1994; 331(3):174-80. DOI: 10.1056/NEJM199407213310307. View

2.
Mistry D, Atkin S, Atkinson H, Gunasekaran S, Sylvester D, Rigby A . Predicting thyroxine requirements following total thyroidectomy. Clin Endocrinol (Oxf). 2011; 74(3):384-7. DOI: 10.1111/j.1365-2265.2010.03940.x. View

3.
Rosenbaum R, BARZEL U . Levothyroxine replacement dose for primary hypothyroidism decreases with age. Ann Intern Med. 1982; 96(1):53-5. DOI: 10.7326/0003-4819-96-1-53. View

4.
Knudsen N, Laurberg P, Rasmussen L, Bulow I, Perrild H, Ovesen L . Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab. 2005; 90(7):4019-24. DOI: 10.1210/jc.2004-2225. View

5.
Biondi B, Fazio S, Carella C, Amato G, Cittadini A, Lupoli G . Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab. 1993; 77(2):334-8. DOI: 10.1210/jcem.77.2.8345037. View